Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.32032 ↗At a glance
Journal article in Pediatric Blood & Cancer, 2025. Written by Adam P Yan and 8 co-authors. Institution: Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada. Major MEDLINE topics: Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Humanized, Immunocompromised Host, Neoplasms. 23 references.
Topics: Kinderkrankenpflege
Abstract (original language)
Children with cancer and hematopoietic stem cell transplant (HSCT) recipients are at high risk for severe respiratory syncytial virus (RSV) infections. Nirsevimab, a long‐acting monoclonal antibody approved in 2023, offers single‐dose seasonal protection. We conducted a single‐center study to assess uptake, factors associated with receipt, and RSV outcomes among eligible patients during the 2024–2025 season. Of 42 eligible patients, 62% received nirsevimab. Delays and missed opportunities for administration were common. RSV occurred in both recipients and non‐recipients, including one RSV‐related death in an unvaccinated patient. Clinic type and healthcare contact influenced uptake. These findings highlight the need for improved implementation strategies to optimize RSV prophylaxis in immunocompromised pediatric populations.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, Toronto, Ontario, Canada.
ORCID profiles: Adam P Yan, Lillian Sung, Sumit Gupta
Cite
APA
Yan, A. P., Feng, Y., Hassanieh, D. E., Starr, A., Yi, M., Schechter-Finkelstein, T., Drynan, J., Sung, L., & Gupta, S. (2025). Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32032
Vancouver
Yan AP, Feng Y, Hassanieh DE, Starr A, Yi M, Schechter-Finkelstein T, et al. Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.32032
BibTeX
@article{Yan2025,
author = {Yan, Adam P and Feng, Yuqing and Hassanieh, Dima El and Starr, Allison and Yi, Martin and Schechter-Finkelstein, Tal and Drynan, Jennifer and Sung, Lillian and Gupta, Sumit},
title = {Nirsevimab for Prevention of RSV Infections for Immunocompromised Children With Cancer and Stem Cell Transplant Recipients: A Single‐Center Experience},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.32032}
}
EUVIMED